Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT06742723

PHASE3

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

Sponsor: AstraZeneca

View on ClinicalTrials.gov

Summary

International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure

Official title: A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants With Chronic Kidney Disease and High Blood Pressure

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

5000

Start Date

2025-03-03

Completion Date

2029-12-18

Last Updated

2026-09-25

Healthy Volunteers

Conditions

Chronic Kidney Disease and Hypertension

Interventions

DRUG

Baxdrostat/dapagliflozin

baxdrostat tablet dapagliflozin tablet

DRUG

Placebo/dapagliflozin

dapagliflozin tablet placebo tablet

Inclusion Criteria: 1. Participants of any sex and gender must be ≥ 18 years of age at the time of signing the informed consent. 2. Participants with (a) or (b): a) eGFR 30-59 mL/min/1.73 m² (local or central laboratory value) AND: * UACR ≥ 30 mg/g (3.39 mg/mmol) and \< 500 mg/g (56.5 mg/mmol) (central laboratory value only), or * UACR ≥ 500 mg/g (56.5 mg/mmol) and ≤ 5000 mg/g (565 mg/mmol) (local or central laboratory value), or * UPCR ≥ 700 mg/g (79 mg/mmol) and ≤ 7000 mg/g (790 mg/mmol) (local laboratory value only). (b) eGFR 60-75 mL/min/1.73 m² (local or central laboratory value) AND: * UACR ≥ 500 mg/g (56.5 mg/mmol) ) and ≤ 5000 mg/g (565 mg/mmol) (local or central laboratory value), or * UPCR ≥ 700 mg/g (79 mg/mmol) and ≤ 7000 mg/g (790 mg/mmol) (local laboratory value only) 3. \[obsolete\] 4. Participants with history of HTN and a SBP ≥ 130 mmHg (the most recent value within 4 weeks prior to screening or at the Screening Visit) and ≥ 120 mmHg at the Randomisation Visit. 5. Stable and maximum tolerated dose of an ACEi or an ARB (not both) for at least 4 weeks prior to Screening Visit. 6. Participants with: 1. Serum or plasma potassium ≥ 3.0 and ≤ 4.8 mmol/L if eGFR ≥ 45 mL/min/1.73 m2 (local or central laboratory values) 2. Serum or plasma potassium ≥ 3.0 and ≤ 4.5 mmol/L if eGFR \< 45 mL/min/1.73 m2 (local or central laboratory values) Exclusion Criteria: 1. Systolic blood pressure \> 180 mmHg, or diastolic BP \> 110 mmHg at screening. 2. Known hyperkalaemia, defined as potassium of ≥ 5.5 mmol/L within 3 months at screening. 3. Serum sodium \< 135 mmol/L (central or local laboratory values obtained within 4 weeks prior to screening or at the Screening Visit). 4\. Participants with T1DM will be excluded, except: 1. For US only: patients with T1DM treated with SGLT2i for at least 4 months, without DKA during that period, and who have experience with ketone monitoring are eligible for inclusion. 2. For Japan only: patients with T1DM treated with dapagliflozin 10 mg for at least 4 months, without DKA during the period of dapagliflozin treatment are eligible for inclusion. 5 Uncontrolled T2DM with HbA1c \> 10.5% (\> 91 mmol/mol) (central or local laboratory values obtained within 3 months prior to screening or at the Screening Visit). 6 New York Heart Association functional HF class IV at screening. 7 Stroke, transient ischaemic cerebral attack, valve implantation or valve replacement, carotid surgery, or carotid angioplasty, acute coronary syndrome, or hospitalisation for worsening heart failure within previous 3 months prior to randomisation. 8 Documented history of adrenal insufficiency. 9 Any dialysis (including for acute kidney injury) within 3 months prior to Screening Visit. 10 Any acute kidney injury within 3 months prior to the Screening Visit. 11 History of organ transplant or bone marrow transplant, or planned organ transplant within 6 months following randomisation (including kidney transplant). 12 Any clinical condition requiring systemic immunosuppression therapy other than maintenance therapy (stable for at least 3 months prior to Visit 1).

Locations (771)

Research Site

Fairhope, Alabama, United States

Research Site

Surprise, Arizona, United States

Research Site

Tucson, Arizona, United States

Research Site

Beverly Hills, California, United States

Research Site

Canoga Park, California, United States

Research Site

Concord, California, United States

Research Site

Fremont, California, United States

Research Site

Fullerton, California, United States

Research Site

Inglewood, California, United States

Research Site

Los Alamitos, California, United States

Research Site

Los Angeles, California, United States

Research Site

San Diego, California, United States

Research Site

San Francisco, California, United States

Research Site

Stanford, California, United States

Research Site

Tarzana, California, United States

Research Site

Arvada, Colorado, United States

Research Site

Denver, Colorado, United States

Research Site

New Britain, Connecticut, United States

Research Site

Washington D.C., District of Columbia, United States

Research Site

Boca Raton, Florida, United States

Research Site

Boynton Beach, Florida, United States

Research Site

Edgewater, Florida, United States

Research Site

Fort Lauderdale, Florida, United States

Research Site

Hollywood, Florida, United States

Research Site

Jacksonville Beach, Florida, United States

Research Site

Lake City, Florida, United States

Research Site

Lakeland, Florida, United States

Research Site

Melbourne, Florida, United States

Research Site

Miami Lakes, Florida, United States

Research Site

Ocoee, Florida, United States

Research Site

Port Charlotte, Florida, United States

Research Site

Port Orange, Florida, United States

Research Site

Riverview, Florida, United States

Research Site

Atlanta, Georgia, United States

Research Site

Augusta, Georgia, United States

Research Site

Austell, Georgia, United States

Research Site

Brunswick, Georgia, United States

Research Site

Conyers, Georgia, United States

Research Site

Decatur, Georgia, United States

Research Site

East Point, Georgia, United States

Research Site

Lawrenceville, Georgia, United States

Research Site

Riverdale, Georgia, United States

Research Site

Honolulu, Hawaii, United States

Research Site

Idaho Falls, Idaho, United States

Research Site

Champaign, Illinois, United States

Research Site

Maywood, Illinois, United States

Research Site

Rockford, Illinois, United States

Research Site

Evansville, Indiana, United States

Research Site

Indianapolis, Indiana, United States

Research Site

Iowa City, Iowa, United States

Research Site

West Des Moines, Iowa, United States

Research Site

Hutchinson, Kansas, United States

Research Site

Kansas City, Kansas, United States

Research Site

Wichita, Kansas, United States

Research Site

Kenner, Louisiana, United States

Research Site

Metairie, Louisiana, United States

Research Site

West Monroe, Louisiana, United States

Research Site

Bethesda, Maryland, United States

Research Site

Boston, Massachusetts, United States

Research Site

Boston, Massachusetts, United States

Research Site

Braintree, Massachusetts, United States

Research Site

New Bedford, Massachusetts, United States

Research Site

Worcester, Massachusetts, United States

Research Site

Ann Arbor, Michigan, United States

Research Site

Detroit, Michigan, United States

Research Site

Garden City, Michigan, United States

Research Site

Saint Joseph, Michigan, United States

Research Site

Kansas City, Missouri, United States

Research Site

Kansas City, Missouri, United States

Research Site

St Louis, Missouri, United States

Research Site

Norfolk, Nebraska, United States

Research Site

Las Vegas, Nevada, United States

Research Site

Eatontown, New Jersey, United States

Research Site

Albany, New York, United States

Research Site

Buffalo, New York, United States

Research Site

New York, New York, United States

Research Site

Greenville, North Carolina, United States

Research Site

Hickory, North Carolina, United States

Research Site

Jacksonville, North Carolina, United States

Research Site

Kinston, North Carolina, United States

Research Site

Morehead City, North Carolina, United States

Research Site

New Bern, North Carolina, United States

Research Site

Raleigh, North Carolina, United States

Research Site

Rocky Mount, North Carolina, United States

Research Site

Sanford, North Carolina, United States

Research Site

Statesville, North Carolina, United States

Research Site

Wilmington, North Carolina, United States

Research Site

Wilmington, North Carolina, United States

Research Site

Winston-Salem, North Carolina, United States

Research Site

Canton, Ohio, United States

Research Site

Cincinnati, Ohio, United States

Research Site

Cincinnati, Ohio, United States

Research Site

Columbus, Ohio, United States

Research Site

Columbus, Ohio, United States

Research Site

Columbus, Ohio, United States

Research Site

Springfield, Oregon, United States

Research Site

Bridgeville, Pennsylvania, United States

Research Site

Butler, Pennsylvania, United States

Research Site

Exton, Pennsylvania, United States

Research Site

Langhorne, Pennsylvania, United States

And 671 more locations on ClinicalTrials.gov

Clinical Research Directory

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

Summary

Key Details

Conditions

Interventions

Eligibility Criteria

Locations (771)